Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clindamycin + tretinoin is a fixed-dose combination topical medication used to treat acne vulgaris, including severe nodular acne, in adults and children over 12 years old. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of bacterial ribosomes, thereby reducing populations of *Propionibacterium acnes* (now *Cutibacterium acnes*), which are implicated in acne pathogenesis. Tretinoin is a retinoic acid derivative (vitamin A analog) that promotes skin cell turnover, reduces sebum production from oil glands, helps keep pores clear, and stimulates collagen synthesis for improved skin texture. The combination provides enhanced efficacy compared to either agent alone by targeting both inflammatory and non-inflammatory lesions while reducing the risk of antibiotic resistance[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + tretinoin.